Clinical characteristics of patients with HBsAg(+) versus HBsAg(-)/HBcAb(+) primary hepatic carcinoma treated by hepatectomy: a comparative analysis
10.3969/j.issn.1001-5256.2015.06.019
- VernacularTitle:行肝癌切除术的HBsAg阳性和HBsAg阴性/抗-HBc阳性原发性肝癌患者临床特点对比分析
- Author:
Keli YANG
1
;
Zhan YANG
;
Yujuan GUAN
Author Information
1. Guangzhou 8th People′s Hospital, Guangzhou 510060, China
- Publication Type:Research Article
- Keywords:
liver neoplasms;
hepatitis B surface antigens;
hepatectomy
- From:
Journal of Clinical Hepatology
2015;31(6):907-
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the differences in clinical characteristics between patients with HBsAg(+) and HBsAg(-)/HBcAb(+) primary hepatic carcinoma (PHC) treated by hepatectomy. MethodsForty-three HBsAg(+) and 18 HBsAg(-)/HBcAb(+) patients who underwent liver resection against PHC from October 2009 to November 2014 in Guangzhou 8th People′s Hospital were selected for the study. The clinical data of the subjects, including sex, age, histological differentiation, intravascular tumor thrombi, and hepatic cirrhosis, were compared, using t test for continuous data, chi-square test for categorical data, and Mann-Whitney U test for non-parametric data. ResultsNo significant differences existed between patients with HBsAg(+) and HBsAg(-)/HBcAb(+) PHC in terms of the age of onset (50.77±12.93 years vs 54.28±9.89 years, t=-1.031, P＞0.05), the incidence of cholangiocarcinoma (2.3% vs 167%, χ2=2.24, P＞0.05), the incidence of hepatic cirrhosis (62.8% vs 44.4%, χ2=1.746, P＞0.05), alpha-fetoprotein level (3638±7869 ng/ml vs 3577±9628 ng/ml, t=0.026, P＞0.05), histological differentiation (Z=-1.085, P＞0.05), and the rate of intravascular tumor thrombi (34.9% vs 22.2%, χ2=0.949, P＞0.05). ConclusionThere are no significant differences in the age of onset and progression of disease between patients with HBsAg(+) and HBsAg(-)/HBcAb(+) PHC treated by hepatectomy. However, given the possibility of occult hepatitis B virus infection, it is necessary to monitor hepatic carcinoma even post HBsAg seroconversion
